Oct 11,2023

PathAI Announces Research Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

PathAI announced it will present research on advances in artificial intelligence (AI) approaches through three posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 11-15 in Boston, Massachusetts, including one poster to be presented in partnership with Flare Therapeutics. The presentations underline the significant strides in AI that can enhance translational and clinical research applications.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Sep 21,2023

Bayer to Collaborate with Hologic in Breast Cancer Imaging

Bayer and Hologic, Inc., today announced an international partnership to deliver contrast-enhanced-mammography (CEM) solutions to improve the detection of breast cancer in multiple countries across Canada, the European and Asia Pacific regions. The partnership brings together the companies' leading technologies (Hologic mammography gantries and Bayer CEM approved injection systems), which enable accurate administration of contrast media during a mammography examination. Bayer and Hologic aim to optimally support radiologists and their teams to effectively implement CEM seamlessly into a radiologist's workflow. CEM is easy to perform in everyday clinical practice and can be used in various clinical settings, such as inconclusive findings in previous imaging procedures, or preoperative assessment of the extent of the disease. It can also be a helpful tool when MRI is unavailable or contraindicated.

COLLABORATION PARTNERSHIP

#product & service

#ai/software

View Analyst & Ambassador Comments
Go to original news
Sep 06,2023

Flatiron Health enters new five-year research collaboration with FDA on real-world data

Flatiron Health today announced its renewed collaboration with the Oncology Center of Excellence (OCE) of the United States Food and Drug Administration (FDA) to jointly develop and implement specific research projects to advance the use of real-world data (RWD) and explore the potential strengths and limitations of using real-world evidence (RWE) for regulatory purposes. The partnership will specifically evaluate RWD study designs and analytic methods through the collaborative development of priority, clinically meaningful research questions regarding care, treatment, and outcomes of patients with cancer.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Oct 03,2023

Exscientia trims pipeline to focus on top cancer prospects

The specialist in applying artificial intelligence to drug discovery is zeroing in on its CDK7 and LSD1 programmes, currently at or near the clinical trials stage, and will offer some others up for partnering. Its partnered projects – including a recently signed $674 million alliance with Merck KGaA in cancer and immunology – are unaffected by the change in strategy. Exscientia’s founder and chief executive, Professor Andrew Hopkins, said the intention is to focus on “well-understood development challenges where our platform can have a clear impact that, if successful, would lead to significant therapeutic benefit.”

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 02,2023

Philips highlights latest advances in CT and MR for precision radiation therapy planning at ASTRO 2023

At the American Society for Radiation Oncology Annual Meeting (ASTRO 2023, October 1-4, 2023, San Diego, USA), Philips will showcase the company’s newest developments in MR and CT to help radiation oncologists target radiation therapy more accurately, including MR-guided radiotherapy for head-and-neck cancer along with the unique radiation oncology capabilities of its Spectral CT 7500 scanner. The Philips Spectral CT 7500 scanner being showcased at ASTRO 2023 offers radiation oncologists a unique CT solution in a single scan. The incremental Spectral CT information can help improve the visibility of a tumor’s boundaries and internal physiology to enhance the accuracy of dose calculation and tumor targeting, helping to reduce the number of scans or modalities needed to plan radiation therapy.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Oct 03,2023 TOP STORY

Massive Bio Pioneers Clinical Trial Recruitment Innovation with Strategic Support from Evernorth Health, Inc.

Massive Bio announces a pivotal advancement in clinical trial recruitment, fortified by a strategic relationship with Evernorth Health. This collaboration is poised to seamlessly integrating innovative AI and personalized concierge services to optimize patient-centric recruitment processes and expand access to advanced care. Dr. Arturo Loaiza-Bonilla, Co-Founder and Chief Medical Officer at Massive Bio, emphasized the commitment to swiftly and efficiently connecting patients with suitable clinical trials: “By amalgamating our advanced, AI-driven technologies with extensive resources, we are poised to streamline clinical trial recruitment, offering swift access to innovative treatments and fostering the acceleration of medical research.”

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 03,2023

Enriching access to multimodal data insights with COTA Connect

COTA is introducing COTA Connect: a powerful new capability to link data with a variety of different supplemental data sources, including linking COTA’s robust real-world clinical data to claims, imaging, socioeconomic data, and more. COTA will provide the tokens that allow linkage to a claims data source, creating a more comprehensive view of patients’ care. This increases granularity of understanding around individuals and populations of interest. According to the press release, COTA can also provide analytical services to analyze the merged dataset and answer relevant research questions.

PRODUCT

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Sep 28,2023

New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer

Veracyte, Inc. has unveiled groundbreaking data at the 2023 American Thyroid Association Annual Meeting, showcasing novel molecular insights into thyroid nodules and cancer made possible by their Afirma Genomic Sequencing Classifier (GSC). Researchers presented findings based on Afirma whole-transcriptome RNA sequencing data, which offer fresh perspectives for advancing thyroid nodule and cancer research. These insights can be explored using Veracyte's Afirma Genomic Resource for Intelligent Discovery (GRID) tool, available for research purposes. The presented data highlight the potential for personalized, whole-transcriptome-based insights in understanding thyroid nodules and cancer's molecular basis. Additionally, they introduce the Afirma GRID tool, which promises to facilitate novel discoveries in this field. The Afirma GRID tool aims to provide comprehensive molecular profiles for thyroid cancer research, fostering a more personalized approach to diagnosis and treatment.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Sep 28,2023

Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023

Veracyte announced that six abstracts highlighting new data from studies evaluating the company’s Decipher Prostate Genomic Classifier and related capabilities will be presented, three as oral presentations, at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2023 taking place October 1-4 in San Diego. The accepted abstracts include data from a large, randomized, phase 3 study that evaluated the ability of Veracyte’s Decipher Prostate test to help inform treatment decisions among patients with high-risk prostate cancer, as well as a study that assessed risk-score correlation between the gene signatures of three commercially available genomic classifiers, including the Decipher Prostate test.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Sep 29,2023

Massive Bio Joins The 5th SOHO Italy Annual Conference

Massive Bio is excited to announce their participation in the 5th SOHO Italy Annual Conference between 3-6th of October, 2023 in Rome.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY